Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2024-04-30 Annual Report
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Annual Report 2023
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2023' and contains comprehensive sections including a Board of Directors report, financial statements, notes to financial statements, auditor's report, and ESG reporting. It covers the full fiscal year 2023 and provides detailed financial performance data, meeting the criteria for an Annual Report (10-K). FY 2023
2024-04-30 English
Photocure ASA: Annual Report 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-04-30 English
Photocure ASA: Annual Report 2023
Report Publication Announcement Classification · 100% confidence The document explicitly states: 'Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2023.' It further mentions that the 'financial statements and annual report for the financial year 2023 are together with the ESG report and auditor's report attached to this notice.' The document is very short (1471 characters) and serves primarily to announce that the full reports (Annual Report, ESG report, Auditor's report) are attached or available elsewhere. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report has been published or is attached should be classified as a Report Publication Announcement (RPA), rather than the full report itself (like 10-K or AR).
2024-04-30 English
Photocure ASA: Annual Report 2023
Report Publication Announcement Classification · 100% confidence The document explicitly states: 'Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2023.' It further mentions that the 'financial statements and annual report for the financial year 2023 are together with the ESG report and auditor's report attached to this notice.' The document is very short (1515 characters) and its primary function is to announce that the full Annual Report (10-K equivalent) and related documents are attached or available elsewhere, rather than being the report itself. According to Rule #2 (The 'MENU VS MEAL' Rule), when a document announces the publication of a report and provides the report as an attachment or link, it should be classified as a Report Publication Announcement (RPA). Although the content relates to the Annual Report, the document's format is an announcement of publication.
2024-04-30 English
Bladder Cancer: pivotal trial results and new real-world evidence, to be presented at AUA 2024, demonstrate improved diagnostic and clinical outcomes with blue light cystoscopy
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Press Release' and announces the company's participation in a medical conference (AUA 2024) where new study results and real-world evidence related to their product (Blue Light Cystoscopy with Cysview®) will be presented. It details the presentation times, topics, and provides general company and product information, concluding with contact details. This structure is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is not a formal financial report (like 10-K or IR) but an announcement of clinical/study updates and participation in an event, it fits best under the 'Earnings Release' category, which often encompasses significant operational or clinical news releases, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure. Given the focus on presenting trial results and company participation, 'ER' is the most appropriate fit among the provided options for a major press announcement, although it is not strictly an earnings report.
2024-04-30 English
Bladder Cancer: pivotal trial results and new real-world evidence, to be presented at AUA 2024, demonstrate improved diagnostic and clinical outcomes with blue light cystoscopy
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a 'Press Release' dated April 30, 2024. It announces the company's participation in an upcoming medical conference (AUA 2024) and details the scientific data (trial results, real-world evidence) that will be presented there. This content is typical of an announcement intended for immediate public dissemination regarding corporate activities, scientific updates, or upcoming events, rather than a formal regulatory filing (like 10-K, IR, or AR) or a detailed investor presentation (IP). Since it is a press release announcing scientific findings and conference participation, it best fits the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, although it is not a standard SEC filing. It is not an Earnings Release (ER) as it does not contain financial results, nor is it a Report Publication Announcement (RPA) as it is announcing participation in an event, not the publication of a formal report.
2024-04-30 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.